不可逆电穿孔治疗不适合热消融技术的肝细胞癌的安全性与疗效:一项回顾性单中心病例系列研究
本研究回顾性纳入2012年3月至2015年6月58例肝硬化患者的75个肝细胞癌肿瘤,因肿瘤位置(48例)或一般状况差(10例)不适合热消融而接受不可逆电穿孔治疗。1、2、3次治疗后完全消融率分别为77.3%、89.3%、92%,中位随访9个月时6个月和12个月总体局部肿瘤无进展生存率分别为87%和70%。术前甲胎蛋白高于200 ng/mL是唯一与总体局部肿瘤无进展生存相关的因素,19%患者出现并发症,3例(5.2%)为Clavien-Dindo III级及以上。
要点
- 不可逆电穿孔治疗后需以MR增强扫描评估消融效果,1个月首次评估、此后每3个月复查。
- 75个肿瘤中1、2、3次治疗后的完全消融率分别为77.3%、89.3%、92%,部分病灶需重复治疗。
- 术前甲胎蛋白高于200 ng/mL者局部肿瘤无进展生存更差(HR 9.94,95%CI 2.82-35.06,P=.0004)。
核心结论
- 不可逆电穿孔可为存在其他常用消融技术禁忌证的肝细胞癌患者提供安全、完全的消融。
研究设计与样本
- 回顾性单中心病例系列研究,经伦理审查委员会批准并豁免知情同意;2012年3月至2015年6月纳入58例肝硬化患者(中位年龄65.4岁,范围41.6-90岁)的75个肝细胞癌肿瘤(中位直径24 mm,范围6-90 mm)。
诊断标准与关键数值
- 75个肿瘤经1次、2次、3次不可逆电穿孔治疗后的完全消融率分别为77.3%(58/75)、89.3%(67/75)、92%(69/75)。
- 中位随访9个月(范围3天至31个月),75个治疗结节6个月和12个月总体局部肿瘤无进展生存率分别为87%(95%CI 77%-93%)和70%(95%CI 56%-81%)。
- 术前血清甲胎蛋白高于200 ng/mL与总体局部肿瘤无进展生存相关(HR 9.94,95%CI 2.82-35.06,P=.0004)。
- 并发症按Clavien-Dindo分级记录:I级3例、II级5例、IV级2例、V级1例。
临床应用与阅片要点
- 治疗适应证为因肿瘤位置(48例)或患者一般状况差(10例)不适合热消融技术。
- 治疗后以MR成像评估治疗反应,时间为治疗后1个月及之后每3个月。
- Child-Pugh B级患者出现III级及以上并发症(肝衰竭)的风险需在治疗决策时权衡,原文报告3例(5.2%)中1例死亡。
- 术前甲胎蛋白高于200 ng/mL提示局部肿瘤无进展生存较差,可用于治疗前风险分层。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To assess the safety and efficacy of irreversible electroporation (IRE) in the treatment of patients with inoperable hepatocellular carcinoma (HCC) who are ineligible for thermal ablative techniques. Materials and Methods This retrospective study was approved by an ethics review board, and the requirement to obtain informed written consent was waived. From March 2012 to June 2015, 58 patients (median age, 65.4 years; range 41.6-90 years) with cirrhosis received IRE for the treatment of 75 HCC tumors. The median tumor diameter was 24 mm (range, 6-90 mm). IRE was selected because of tumor location (48 patients) or the patient's poor general condition (10 patients). Treatment response was assessed with magnetic resonance (MR) imaging 1 month after treatment and every 3 months thereafter. Overall local tumor progression-free survival (PFS) per nodule (including initial treatment failures) was assessed by using the Kaplan-Meier method. The marginal Cox proportional hazards model was used to assess the factors associated with overall local tumor PFS. Complications were recorded and graded according to the Clavien-Dindo classification. Results Of 75 tumors, 58 (77.3%), 67 (89.3%), and 69 (92%) were completely ablated after one, two, and three IRE procedures, respectively. After a median follow-up of 9 months (range, 3 days to 31 months), the 6- and 12-month overall local tumor PFS rates for the 75 treated nodules were 87% (95% confidence interval [CI]: 77%, 93%) and 70% (95% CI: 56%, 81%), respectively. A preablative serum α-fetoprotein level higher than 200 ng/mL (hazard ratio: 9.94 [95% CI: 2.82, 35.06], P = .0004) was the only factor linked with overall local tumor PFS. Complications occurred in 11 of the 58 patients (19%) and were classified as grade I in three patients, grade II in five patients, grade IV in two patients, and grade V in one patient. The three (5.2%) complications classified as grade III or higher were liver failures occurring in patients with Child-Pugh class B disease; one led to death. Conclusion IRE offers safe, complete ablation of HCC tumors in patients with contraindications to other commonly used ablative techniques. © RSNA, 2017 Online supplemental material is available for this article.
引用
- Sutter O, Calvo J, N'Kontchou G, et al. Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series. Radiology. 2017. PMID: 28453431. doi:10.1148/radiol.2017161413
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。